Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
300204 Staidson
- 11.94
- +1.13+10.45%
Market Closed Apr 24 15:00 CST
5.70BMarket Cap-39.80P/E (TTM)
12.40High10.68Low624.66KlotVolume10.76Open10.81Pre Close724.20MTurnover13.24%Turnover RatioLossP/E (Static)477.77MShares12.4052wk High5.98P/B5.63BFloat Cap5.4152wk Low12.97Limit Up471.94MShs Float44.14Historical High8.65Limit Down15.91%Amplitude3.51Historical Low--Dividend TTM11.59Avg Price241.47KlotAsk--Div YieldTTM100Lot Size338.63KlotBid
About Staidson Company
The company was founded in August 2002 and listed on the Shenzhen Stock Exchange GEM on April 15, 2011. The company falls under the “C27 Pharmaceutical Manufacturing Industry” category in the China Securities Regulatory Commission's listed company industry classification. As an innovative biopharmaceutical enterprise, the company has a complete industrial chain and is a high-tech enterprise with a relatively complete R&D, production, quality management, marketing and supporting system. The company's main business is R&D, production and marketing of innovative drugs, especially biopharmaceuticals, with independent intellectual property rights. The company's main products are the innovative biological drug threeptiscene (mouse nerve growth factor for injection) and the specialty product sultaiqing (compound polyethylene glycol electrolyte powder (IV)). The company received honors such as the Beijing Economic and Technological Development Zone's top 50 tax payment growth enterprises in 2011, high-tech enterprises in Beijing, innovative pilot enterprises in the Zhongguancun National Independent Innovation Demonstration Zone, and the third prize of the Beijing Science and Technology Progress Award.
Company Profile
Short Name-A舒泰神
Symbol-A300204
Company NameStaidson (Beijing) Biopharmaceuticals Co., Ltd.
Listing DateApr 15, 2011
Issue Price52.50
Shares Offered16.70M share(s)
FoundedAug 16, 2002
Legal Representativezhiwen zhou
General Managerchao wang
Secretarymaorong yu
Accounting FirmTianheng Certified Public Accountants (Special General Partnership)
Securities Representativehan cai
Legal CounselBeijing Kangda Law Firm
Employees448
Phone010-67875255
Office AddressNo. 36, Jinghai 2nd Road, Beijing Economic and Technological Development Zone, Beijing
Zip Code100176
Registered AddressNo. 36, Jinghai 2nd Road, Beijing Economic and Technological Development Zone, Beijing
Fax010-67875255
Emailsecurities@staidson.com
Websitehttp://www.staidson.com
Business License110302004270284
BusinessProduction of tablets, hard capsules, powders, oral solutions, and therapeutic biological products (drug production license valid until December 7, 2025); technology development, technology transfer, technical consulting, technical services for pharmaceuticals and biological products; import and export of goods, import and export agents, technology import and export. (Market players independently choose business projects and carry out business activities according to law; for projects subject to approval according to law, they carry out business activities according to the approved content after approval by the relevant departments; they are not allowed to engage in business activities prohibited or restricted by national and municipal industrial policies.)
Company Executives
- Name
- Position
- Salary
- zhiwen zhou
- Chairman, Directors, Chairman of the Strategy Committee
- 1.16M
- rongqin zhang
- Directors, Strategy Committee Member, Member of the Remuneration and Assessment Committee
- 1.60M
- lianchun yang
- Directors, Nomination Committee Members, Strategy Committee Member, Audit Committee Member
- 1.50M
- xiaoyan wang
- Directors
- --
- qishun lu
- Independent Directors, Chairman of the Audit Committee, Nomination Committee Members
- 52.20K
- li zhao
- Independent Directors, Strategy Committee Member, Chairman of the Remuneration and Assessment Committee, Audit Committee Member
- 136.80K
- jiajun zhao
- Independent Directors, Chairman of the Nomination Committee, Strategy Committee Member, Member of the Remuneration and Assessment Committee
- 136.80K
- maorong yu
- Board Secretary, Deputy General Manager
- 878.90K
- han cai
- Securities Affairs Representative
- --
- hongshan zhang
- Chairman of the Supervisory Board, Auditors
- 766.70K
- tao li
- Auditors
- 533.30K
- chao wang
- General Manager, Head of Finance
- 1.54M
- shicheng li
- Deputy General Manager, Chief Financial Officer
- 946.70K
- yujing feng
- Director of Internal Audit
- 477.00K
- lei zhang
- Director of Human Resources
- --
- yanfang sun
- Chief Engineer
- 272.00K
- jingfeng wang
- General Manager of Marketing Self-Operating Division
- --
- lei tian
- Director of Production Center
- --
- xuelian bai
- General Manager of Clinical Research Center
- --
- hong zheng
- Employee Supervisors
- 600.10K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs